August 03, 2018
A certified class of investors in Juno Therapeutics told a Washington federal judge on Thursday that it has reached a $24 million settlement to resolve claims that the biopharmaceutical company's failure to disclose the death of one of its immunotherapy patients led to a 30 percent drop in its share price.
October 24, 2017
Investors claiming the immunotherapy company Juno Therapeutics failed to inform them of the health risks associated with one of its drugs received class certification on Tuesday in Washington federal court, and Pomerantz LLP was appointed lead class counsel.